The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
Open accessAbstract
Background Ivacaftor is a safe, effective treatment for cystic fibrosis (CF) in patients aged ≥6 years with a CFTR gating mutation. This open-label, multicenter, phase 3 study assessed ivacaftor in children aged 2–5 years. Methods Children aged 2–5 years with a CFTR gating mutation received ivacaftor (<14 kg: 50 mg every 12 hours; ≥14 kg: 75 mg every 12 hours) for 4 days (Part A; n=9) or 24 weeks (Part B; n=34). Primary outcomes were pharmacokinetics (PK) and safety. Other markers of disease were also evaluated. Findings Ivacaftor PK was similar to that reported in adults. Common adverse events in Part B included cough (n=19; 55·9%) and vomiting (n=10; 29·4%). Five patients (15%) experienced liver function test (LFT) elevations >8× ULN (study drug interrupted, n=4; study discontinuation, n=1). At week 24, sweat chloride improved on average by −46·9 mmol (SD 26·2, p<0·0001), BMI z-score by 0·4 (SD 0·4, p<0·0001), fecal elastase by 99·8 (138·4) μg/g (p=0·0009) and immunoreactive trypsinogen by −20·7 ng/mL (SD 24·0, p=0.0002). Interpretation Ivacaftor appears safe and beneficial in young CF children with a gating mutation followed for 24 weeks. The safety profile was similar to that seen in older CF patients, although the frequency of LFT elevations suggests consideration of more frequent monitoring in younger children, particularly those with a history of elevated LFTs. Improvements in sweat chloride and nutritional parameters, with a suggestion of enhanced pancreatic function were observed. Funding Vertex Pharmaceuticals Incorporated www.clinicaltrials.gov identifier:
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citationBeydon, N., Davis, S. D., Lombardi, E., Allen, J. L., Arets, H. G. M., Aurora, P., Bisgaard, H., Davis, G. M., Ducharme, F. M., Eigen, H., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-642st · Cited by 1,250
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,094
Davies, J. C., Wainwright, C. E., Canny, G. J., Chilvers, M. A., Howenstine, M. S., Munck, A., Mainz, J. G., Rodriguez, S., Li, H., Yen, K., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0153oc · Cited by 510
Self-citationNutrition in patients with cystic fibrosis: a European Consensus
Sinaasappel, M., Stern, M., Littlewood, J., Wolfe, S., Steinkamp, G., Heijerman, H. G. M., Robberecht, E., & Döring, G. (2002) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00032-2 · Cited by 477
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Yu, H., Burton, B., Huang, C.-J., Worley, J., Cao, D., Johnson, J. P., Urrutia, A., Joubran, J., Seepersaud, S., Sussky, K., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.12.005 · Cited by 423
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G., & Higgins, M. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.09.005 · Cited by 394
Multiple-Breath Washout as a Marker of Lung Disease in Preschool Children with Cystic Fibrosis
Aurora, P., Bush, A., Gustafsson, P., Oliver, C., Wallis, C., Price, J., Stroobant, J., Carr, S., & Stocks, J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-895oc · Cited by 381
Cited by
Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32542-3 · Cited by 682
Self-citationTezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522
Self-citationRole of CFTR in epithelial physiology
Saint-Criq, V., & Gray, M. A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2391-y · Cited by 433
Cystic fibrosis in the year 2020: A disease with a new face
De Boeck, K. (2020) · Acta Paediatrica · doi:10.1111/apa.15155 · Cited by 332
Ratjen, F., Hug, C., Marigowda, G., Tian, S., Huang, X., Stanojevic, S., Milla, C. E., Robinson, P. D., Waltz, D., Davies, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30215-1 · Cited by 294
Self-citation
Metadata
- Authors
- Davies, J. C., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Robertson, S., Green, Y., Cooke, J., & Rosenfeld, M.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 4
- Issue
- 2
- Pages
- 107-115
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2254054106
- Cited by
- 347
- References
- 25
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. https://app.cochat.ai/papers/10.1016/s2213-2600(15)00545-7
- The paper
- Davies, J. C., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Robertson, S., Green, Y., Cooke, J., & Rosenfeld, M. (2016). Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(15)00545-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.